4//SEC Filing
Whitfield Dianne C. 4
Accession 0001819790-24-000044
CIK 0001819790other
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 7:04 PM ET
Size
11.2 KB
Accession
0001819790-24-000044
Insider Transaction Report
Form 4
Whitfield Dianne C.
Chief Human Resources Officer
Transactions
- Exercise/Conversion
Common Stock
2024-03-15+11,711→ 38,495 total - Sale
Common Stock
2024-03-18$30.60/sh−4,314$132,008→ 34,181 total - Exercise/Conversion
Restricted Stock Units
2024-03-15−4,463→ 8,925 total→ Common Stock (4,463 underlying) - Exercise/Conversion
Restricted Stock Units
2024-03-15−7,248→ 21,745 total→ Common Stock (7,248 underlying)
Footnotes (5)
- [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F4]RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service.
- [F5]RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2024, March 15, 2025, March 15, 2026 and March 15, 2027, subject to the Reporting Person's continuous service.
Documents
Issuer
Tarsus Pharmaceuticals, Inc.
CIK 0001819790
Entity typeother
Related Parties
1- filerCIK 0001839516
Filing Metadata
- Form type
- 4
- Filed
- Mar 18, 8:00 PM ET
- Accepted
- Mar 19, 7:04 PM ET
- Size
- 11.2 KB